Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young Plasma Infusion in Frailty and HFpEF
NCT04241159Phase 1Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of young fresh frozen plasma in frailty syndrome and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Frequency of adverse events. Planned start May 2020; status: withdrawn.
02
Drugs
young fresh frozen plasma
03
Conditions
frailty syndromeheart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04241159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241159.